The company has a dividend yield of 2.09% with the ex dividend date set at 23-2-2023 (DMY).

AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006 and Personalis The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. Its marketed products also comprise Synagis for respiratory syncytial virus Fluenz Tetra/FluMist Quadrivalent for Influenza and Vaxzevria and Evusheld for covid-19. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.ĪstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.